Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures

Pharmacy Practice

Volumn 4, Issue 4, 2006, Pages 168-178

  Nishimura, Tsutomu ^a   Tada, Harue ^a   Nakagawa, Masatsugu ^a   Teramukai, Satoshi ^a   Matsui, Shigeyuki ^b   Fukushima, Masanori ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Decision making; Gefitinib; Interstitial; Japan; Lung diseases; Organization; Postmarketing; Products surveillance

Indexed keywords

DOCETAXEL; GEFITINIB; PLATINUM COMPLEX;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL DECISION MAKING; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE MODEL; DRUG APPROVAL; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; EXTERNAL VALIDITY; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; JAPAN; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; NONHUMAN; PNEUMONIA; REGISTER; RISK FACTOR;

EID: 43949132326     PISSN: None     EISSN: 18863655     Source Type: Journal    
DOI: None     Document Type: Article

References (75)